Skip to content
MARKETS / NASDAQ / CRIS
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Curis Inc. CRIS

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.4M
▼ 13.4% YoY
$-7.6M
In brief

What this company does

We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948). In January 2026, we completed a private placement, or January 2026 PIPE Financing, for net proceeds of approximately $18.6 million. In August 2025, we announced a Phase 2 open label clinical study of emavusertib in combination with zanubrutinib in frontline CLL (CA-4948-203, NCT07271667), also known as the TakeAim CLL study. As of December 31, 2025, we had $5.1 million in cash and cash equivalents. As of February 9, 2026, we had 24 employees, of which 20 are full-time.

Written from the business description in Curis, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 March 2026. Every sentence was checked against that document before publication.

Growth
USD 9.4M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.4 · Net income -7.6
8.0M16.0M-25.0M-50.0M200920112013201520172019202120232025
Compound annual growth
−2.4%
−2.7%
+1.8%
−3.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−80 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -60.5% · Net -80.3%
-500%200920112013201520172019202120232025
ROE
FY2024 · ROE -634.7%
-200%-400%-600%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -38.4
-20M-40M200920112013201520172019202120232025

Total assetsUSD 20.0M
EquityUSD 5.5M
CashUSD 5.1M
Gross debtUSD 0.00
Net debtUSD -5.1M
Current ratio0.49×

The company holds more cash than debt.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B·············−0.0−0.0−0.0·
Income tax $B0.00.0···············
Net income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.58−6.88−8.96−12.14−0.50−0.61−0.97−0.98−1.79−0.45−0.48−0.22−0.15−0.21−0.13−0.06−0.15
Dividend / sh $·················
Payout %·················
ROE %·−634.7−143.2−82.6−41.0−61.8·−334.2−199.5−128.6−125.1−50.0−31.0−44.3−23.1−11.3−29.7
Shares out B0.010.010.010.000.090.090.030.030.030.140.130.090.090.080.080.08·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 11 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image